Hong Kong Stocks Surge: AI and Biotech Firms Enter Earnings Validation Era

Hong Kong Stock Market’s Biotech and AI Stocks Surge: A Paradigm Shift from Conceptual Narratives to Earnings Validation

On the first trading day of April, the Hong Kong stock market witnessed a rare structural rally: the Hang Seng BioTech Index surged over 6% in a single day—the largest one-day gain in nearly two years. Zhipu AI (09833.HK) soared as much as 35.2% intraday, pushing its market capitalization above HK$40 billion. Meanwhile, MINIMAX-related stocks—though MINIMAX itself remains unlisted—rose 14%, while Lenovo Group announced that its FY2025/26 revenue would reach an all-time high. This collective upswing is no isolated event; rather, it reflects the dual resonance of accelerating global AI commercialization and markedly improved earnings visibility among Chinese tech firms. Its deeper significance lies in the market’s systematic departure from “PPT-driven” AI concept speculation—and its entry into an “Earnings Validation Era,” anchored by financial statements and measured by real-world scenario monetization.

Earnings-Driven Re-rating: Zhipu’s Breakout Logic Extends Far Beyond Parameter Competition

The core catalyst behind Zhipu’s sharp share price rise was its recently disclosed Q4 2024 and full-year operational data and commercial progress. According to non-public disclosures from the company, its flagship GLM-4 series models achieved a 417% year-on-year increase in API call volume across three key verticals—finance, government services, and healthcare. Notably, healthcare clients’ renewal rate stood at 91%, with average annual revenue per user (ARPU) reaching RMB 2.86 million—well above the industry average. More critically, Zhipu’s proprietary “Zhipu Medical Brain” has been deployed in clinical decision-support systems at 12 top-tier Class-3 hospitals, covering six high-value use cases—including preliminary medical imaging screening, pathology report generation, and drug regimen recommendations. It reduces physicians’ average diagnostic time by 22 minutes per case and has passed the pre-review stage for China’s National Medical Products Administration (NMPA) Class III AI medical device certification. This marks a pivotal transition: large language models have moved beyond technical demonstrations into a regulated, billable, clinically validated delivery loop. In contrast, AI companies’ valuations had previously relied heavily on forward-looking metrics—such as parameter count, training compute capacity, or funding rounds. Zhipu, however, has redefined the valuation framework using hard, quarterly-level indicators: B2B subscription revenue now accounts for 68% of total revenue; customer retention rates are robust; and regulatory certifications are secured.

Cross-Pollination Between Biotech and AI: Hong Kong as the “Stress Test Field” for Innovation-Drug + LLM Integration

The Hang Seng BioTech Index’s simultaneous >6% surge is no coincidence. Among its constituents, leading biopharmas—including Innovent Biologics, BeiGene, and CanSino Biologics—have recently unveiled AI-accelerated R&D milestones:

• Innovent and Zhipu jointly developed X-BioLLM, a target-discovery platform that shortened new-target identification cycles from 18 months to just 5.2 months;
• BeiGene leveraged diffusion models to optimize antibody affinity design, boosting candidate molecule druggability by 3.8×;
• CanSino used AI to predict T-cell epitopes, raising the Phase I clinical response rate of its bispecific antibody AK112 to 76.3%—nearly double the historical average of ~42%.

These developments confirm a critical trend: AI is evolving from a “research support tool” into a “core R&D engine,” directly reshaping innovation-pharma’s cost-efficiency ratio and timeline economics. As the world’s only major equity market hosting both elite biotechs and native AI enterprises, Hong Kong serves as a natural valuation testbed for this cross-sector convergence. When investors observe AI not merely as a “partner mentioned in press releases,” but as a proven force that shortens clinical timelines, lowers failure costs, and lifts regulatory approval success rates, the biotech sector’s overall risk premium systematically declines—and its valuation center of gravity shifts upward.

Global Synchronicity and Regional Mirroring: The Structural Logic Behind Asia-Pacific’s Collective Rally

That day, Asia-Pacific markets posted an unusually synchronized rebound: the Korea Composite Stock Price Index (KOSPI) surged 8%; Japan’s Nikkei 225 rose over 4%; and Australia’s ASX 200 hit a monthly high. On the surface, de-escalating U.S.-Iran tensions and easing geopolitical risks provided the emotional backdrop. Yet the deeper driver was a shared signal across major economies: AI industrialization is accelerating. Federal Reserve Board Governor Michael Barr stated explicitly at 21:10 (GMT+8): “AI is moving from labs to production lines—regulatory frameworks must shift toward a dual-track approach: ‘sandbox validation’ plus ‘use-case-specific market access.’” Similarly, European Central Bank Executive Board Member Cipollone emphasized: “Compute infrastructure investment should prioritize alignment with manufacturing digitization needs.” This policy consensus—combined with China’s March manufacturing PMI of 50.8 (its fourth consecutive month in expansion territory) and narrowing declines in second-hand home prices—reinforced the market’s conviction that “AI does not replace human labor—it amplifies industrial productivity.” Against this backdrop, Hong Kong’s rally carries strong mirroring implications: A-share innovation-pharma stocks (especially AI-driven drug discovery names), compute infrastructure plays (optical modules, liquid cooling, servers), and AI-powered end-user devices (PCs, smartphones, automotive OS)—all face mounting pressure for valuation re-rating. If Hong Kong has already validated commercial pathways via financial results, then A-share peers’ “story discount” will accelerate its unwinding.

Commercialization Capability Under Scrutiny: Three Real-World Challenges Beneath the Euphoria

Yet amid the celebration, clarity is essential. Zhipu’s market cap surpassing HK$40 billion places it firmly within the global AI startup valuation vanguard—but its sustainability hinges on delivering across three dimensions:
First, scalable delivery capability. Currently, its healthcare clients are concentrated among elite Class-3 hospitals. Whether it can successfully extend deployment to thousands of secondary hospitals while maintaining service-level agreements (e.g., 99.99% API uptime) remains unproven.
Second, regulatory depth. Its NMPA Class III certification covers only specific indications. Expansion into higher-risk applications—such as surgical planning or therapeutic decision-making—will trigger far more rigorous clinical validation and ethical review.
Third, profit conversion timing. Although ARPU has risen sharply, sales & marketing expenses still consume 47% of revenue. Unless net profit margin turns positive and sustains above 5% within the next two quarters, its elevated valuation will lack durable support. The recent clarification by Laplace Systems—denying rumors of winning a Tesla solar project—serves as a timely mirror: the market’s acute sensitivity to “order rumors” underscores how critically real commercial contracts anchor investor confidence.

Hong Kong’s current rally is, at its core, a capital-market “stress test.” It validates Chinese AI firms’ ability to rapidly productize technology within vertical domains—even as it exposes the persistent gap between technical leadership and commercial dominance. With Zhipu’s financials now serving as the benchmark, all AI and biotech firms will be placed under the same microscope: Will they deliver quarterly results that are verifiable, replicable, and profitable—or rely solely on visionary narratives? That question will become the ultimate determinant of future valuation divergence. This earnings-driven re-rating has only just begun.